Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. HART Investigators.

[1]  H. Hellstrom.  Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. , 1991, Circulation.

[2]  A. Tonkin,et al.  A Randomized Comparison of Intravenous Heparin With Oral Aspirin and Dipyridamole 24 Hours After Recombinant Tissue‐Type Plasminogen Activator for Acute Myocardial Infarction , 1991, Circulation.

[3]  J. Hsia,et al.  A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators. , 1990, The New England journal of medicine.

[4]  R. Califf,et al.  Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group. , 1990, Circulation.

[5]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico..  MEDICAL SCIENCE GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction , 1990, The Lancet.

[6]  J. Gore,et al.  Comparison of immediate invasive, delayed invasive, and conservative strategies after tissue-type plasminogen activator. Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II-A trial. , 1990, Circulation.

[7]  E. Topol,et al.  A randomized pilot trial of brief versus prolonged heparin after successful reperfusion in acute myocardial infarction. , 1990, The American journal of cardiology.

[8]  M. Verstraete.  Thrombolytic Treatment of Acute Myocardial Infarction , 1985 .

[9]  D. Doyle,et al.  Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. , 1989, The New England journal of medicine.

[10]  K. Lee,et al.  A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. , 1989, Circulation.

[11]  Sarah Parish,et al.  Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. , 1988, Journal of the American College of Cardiology.

[12]  K. Friedman,et al.  Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. , 1988, Blood.

[13]  F. Sheehan,et al.  Improved survival up to four years after early coronary thrombolysis. , 1988, The American journal of cardiology.

[14]  M. Parker,et al.  Role of heparin after intravenous thrombolytic therapy for acute myocardial infarction. , 1987, The American journal of cardiology.

[15]  G. Raskob,et al.  Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. , 1986, The New England journal of medicine.

[16]  M. Simoons,et al.  IMPROVED SURVIVAL AFTER EARLY THROMBOLYSIS IN ACUTE MYOCARDIAL INFARCTION A Randomised Trial by the Interuniversity Cardiology Institute in The Netherlands , 1985, The Lancet.

[17]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.

[18]  E. Veys,et al.  HL-A AND INFECTIVE SACROILEITIS , 1974 .